Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M.

J Antimicrob Chemother. 2019 Jun 1;74(6):1670-1678. doi: 10.1093/jac/dkz068.

PMID:
30815689
2.

Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Chon S, Gupta A, Golub JE, Dooley KE.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01383-18. doi: 10.1128/AAC.01383-18. Print 2018 Nov.

3.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492

Supplemental Content

Loading ...
Support Center